Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative

Am Heart J. 2006 Jul;152(1):170-6. doi: 10.1016/j.ahj.2005.09.005.

Abstract

Background: Estradiol reduced progression of ultrasonographic carotid disease in a randomized trial. No trials of unopposed estrogen for prevention of lower extremity arterial disease or aortic aneurysm have been conducted.

Methods: The Estrogen Alone trial randomized 10739 postmenopausal women with prior hysterectomy, mean age 63.6 +/- 7.3 years, to conjugated equine estrogens (CEE 0.625 mg/d) or placebo and documented health outcomes over an average of 7.1 +/- 1.6 years.

Results: A trend toward increased risk of peripheral arterial events with CEE was observed (hazard ratio [HR] 1.32, 95% CI 0.99-1.77). Carotid arterial events (HR 1.19, 95% CI 0.82-1.74), lower extremity arterial events (HR 1.41, 95% CI 0.86-2.32), and abdominal aortic aneurysm (HR 2.40, 95% CI 0.92-6.23) were more frequent, but not individually significant, in the CEE group. However, the composite of lower extremity arterial disease/abdominal aortic aneurysm was significantly more frequent among women assigned to CEE (HR 1.63, 95 % CI 1.05-2.51). In subgroup analyses, no clear pattern of risk with CEE was apparent by age or by time since menopause.

Conclusions: Unopposed CEE conferred no protection against peripheral arterial disease among generally healthy postmenopausal women; in fact, there was a suggestion of increased risk.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Aortic Aneurysm, Abdominal / chemically induced
  • Aortic Aneurysm, Abdominal / epidemiology
  • Aortic Aneurysm, Abdominal / prevention & control*
  • Arterial Occlusive Diseases / chemically induced
  • Arterial Occlusive Diseases / epidemiology
  • Arterial Occlusive Diseases / prevention & control*
  • Carotid Artery Diseases / chemically induced
  • Carotid Artery Diseases / epidemiology
  • Carotid Artery Diseases / prevention & control*
  • Comorbidity
  • Coronary Artery Disease / epidemiology
  • Estrogens / adverse effects
  • Estrogens / therapeutic use*
  • Estrogens, Conjugated (USP) / adverse effects
  • Estrogens, Conjugated (USP) / therapeutic use*
  • Female
  • Humans
  • Lower Extremity
  • Middle Aged
  • Proportional Hazards Models
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Women's Health

Substances

  • Estrogens
  • Estrogens, Conjugated (USP)